ALXO News and Press, ALX Oncology Holdings Inc. From 04/30/21

Gainers: Brooklyn ImmunoTherapeutics (BTX) +38%, Motus GI MOTS +32%, CryoLife (CRY) +16%, Mesoblast MESO +14%, Arcutis Biotherapeutics (ARQT) +10%.Losers: Ardelyx (ARDX) -13%, Pacific Biosciences of California (PACB) -13%, ALX Oncolo...

BURLINGAME, Calif., April 21, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that our Phase 1b study of ALX148 in patien...

The post-grant review period for the granted U.S. Patent No. 10,696,730 ended on March 30, 2021, ALX Oncology Holdings ([[ALXO]] +1.0%) announced today.The patent trial and appeal board can initiate a post-grant review process if a third party files a petition during the nine-month-...

The post-grant review period for U.S. Patent 10,696,730 covering the composition of matter of ALX148 ended on March 30, 2021. This patent provides coverage of ALX148 until at least 2036, not including term adjustments or extensions. BURLINGAME, Calif., April 05, 2021...

Do You Have These Trending Biotech Stocks On Your Watchlist This Week? Biotech companies play a major role in advancing longevity and medicine, even more so as we recover from the coronavirus pandemic. It is this importance that made biotech stocks a major hit among investors, a...

ALX Oncology (ALXO): Q4 GAAP EPS of -$0.50 misses by $0.15.Cash and cash equivalents as of December 31, 2020 were $434.2 million. ALX Oncology believes its current cash and cash equivalents are sufficient to fund planned operations through 2024.Press Release For further details see: ALX...

BURLINGAME, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today reported financial results for the fourth quarter and ...

BURLINGAME, Calif., March 15, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the appointment of Sophia Randolph, M.D., P...

The following slide deck was published by ALX Oncology Holdings Inc. in conjunction with this event. For further details see: ALX Oncology Holdings (ALXO) Investor Presentation - Slideshow

ALX Oncology (ALXO) and privately held Tallac Therapeutics announce collaboration to jointly develop, manufacture, and commercialize a novel class of cancer immunotherapeutics.Under the terms of the agreement, the companies will share equally in the cost of research and development and a...